Published in J Control Release on August 12, 2011
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother (2012) 1.23
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother (2012) 1.14
Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One (2012) 1.08
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci U S A (2012) 1.03
Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother (2012) 0.95
SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One (2011) 0.87
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. Virology (2014) 0.87
Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Clin Chim Acta (2014) 0.86
Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV. Antimicrob Agents Chemother (2014) 0.85
Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. J Antimicrob Chemother (2013) 0.83
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc. Mater Sci Eng C Mater Biol Appl (2016) 0.77
Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. J Pharm Sci (2014) 0.77
Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues. AIDS Res Hum Retroviruses (2016) 0.76
Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay. J Chromatogr B Analyt Technol Biomed Life Sci (2016) 0.75
Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration. Antimicrob Agents Chemother (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
A vaginal fluid simulant. Contraception (1999) 3.36
Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov (2002) 2.78
Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis (2008) 2.25
Commercial sex and the spread of HIV in four cities in sub-Saharan Africa. AIDS (2001) 2.16
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr (2009) 1.89
Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis (2008) 1.81
Advances in microbicide vaginal rings. Antiviral Res (2010) 1.76
Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav (2007) 1.69
Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother (2007) 1.58
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis (2005) 1.54
Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm (2008) 1.51
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One (2010) 1.48
Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother (2005) 1.48
Topical silicone gel versus placebo in promoting the maturation of burn scars: a randomized controlled trial. Plast Reconstr Surg (2010) 1.48
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother (2008) 1.46
In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception (2004) 1.40
Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr (2010) 1.35
The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev (2005) 1.33
Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm (2006) 1.32
Fourteen-day safety and acceptability study of the universal placebo gel. Contraception (2006) 1.27
Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci (2008) 1.20
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
Semisolid systems containing propolis for the treatment of periodontal disease: in vitro release kinetics, syringeability, rheological, textural, and mucoadhesive properties. J Pharm Sci (2007) 1.10
Mucoadhesive drug delivery systems. J Pharm Bioallied Sci (2011) 1.07
Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone. J Control Release (2001) 1.05
Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine (2009) 1.03
Characterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery. Biomacromolecules (2009) 1.00
Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release (2003) 0.99
Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy. Pharm Res (1997) 0.97
Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives. Int J Gynaecol Obstet (1999) 0.97
The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm (2004) 0.95
Rheological properties of vaginal hydrophilic polymer gels. Curr Drug Deliv (2009) 0.94
Systematic study of the flow behaviour and mechanical properties of Carbopol Ultrez 10 hydroalcoholic gels. Eur J Pharm Biopharm (2002) 0.94
Effect of temperature and pH on contraceptive gel viscosity. Contraception (2003) 0.91
Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: optimisation by an artificial neural network. Int J Pharm (2010) 0.91
In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother (2007) 0.86
Assemblies for in vitro measurement of bioadhesive strength and retention characteristics in simulated vaginal environment. Drug Dev Ind Pharm (2002) 0.86
Retention and distribution of two 99mTc-DTPA labelled vaginal dosage forms. Int J Pharm (2004) 0.84
Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions. Int J Pharm (2010) 0.81
The mucosal toxicity of different benzalkonium chloride analogues evaluated with an alternative test using slugs. Pharm Res (2001) 0.81
The evaluation of the local tolerance of vaginal formulations containing dapivirine using the Slug Mucosal Irritation test and the rabbit vaginal irritation test. Eur J Pharm Biopharm (2005) 0.81
Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. Virology (2008) 0.80
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
AIDS vaccine models: challenging challenge viruses. Nat Med (2002) 3.92
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol (2007) 3.24
Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell (2012) 3.22
Online submission makes authors do all the work. Nature (2005) 3.21
SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS (2002) 3.19
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 3.00
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med (2004) 2.58
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood (2006) 2.40
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A (2011) 2.39
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Target cells in vaginal HIV transmission. Microbes Infect (2003) 2.36
Public health. Regulatory challenges in microbicide development. Science (2004) 2.28
Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses (2004) 2.22
Whither or wither microbicides? Science (2008) 2.17
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology (2005) 2.13
HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol (2006) 2.12
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A (2013) 2.10
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts. J Virol (2006) 2.05
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology (2006) 1.97
The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. J Infect Dis (2012) 1.96
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med (2005) 1.92
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90
Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS (2006) 1.88
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87
Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A (2009) 1.87
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique. Pharm Res (2010) 1.76
Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med (2007) 1.76
A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.76
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology (2004) 1.72
Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5. Blood (2010) 1.72
Genetic requirements for the survival of tubercle bacilli in primates. J Infect Dis (2010) 1.69
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2005) 1.68
Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J Virol (2005) 1.66
Classic AIDS in a sooty mangabey after an 18-year natural infection. J Virol (2004) 1.66
Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: potential for enhanced topical photodynamic therapy. J Control Release (2008) 1.65
The DosR Regulon Modulates Adaptive Immunity and Is Essential for Mycobacterium tuberculosis Persistence. Am J Respir Crit Care Med (2015) 1.63
Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol (2005) 1.63
HIV swiftly guts the immune system. Nat Med (2005) 1.61
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology (2006) 1.59
The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood (2009) 1.59
Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology (2006) 1.58
Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med (2006) 1.56
Vaginal microbicides: moving ahead after an unexpected setback. AIDS (2007) 1.56
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A (2009) 1.55
Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol (2013) 1.54
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A (2009) 1.53
Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol (2011) 1.53
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology (2014) 1.53
HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS (2009) 1.49
Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother (2005) 1.48